Jonathan Eidman, DPT | |
2815 Buford Dr Ste 102, Buford, GA 30519-8151 | |
(770) 271-4413 | |
Not Available |
Full Name | Jonathan Eidman |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 2815 Buford Dr Ste 102, Buford, Georgia |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1487178646 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208100000X | Physical Medicine & Rehabilitation | PT013022 (Georgia) | Secondary |
225100000X | Physical Therapist | PT013022 (Georgia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jonathan Eidman, DPT 1200 Corporate Dr Ste 400, Hoover, AL 35242-5424 Ph: (866) 518-0283 | Jonathan Eidman, DPT 2815 Buford Dr Ste 102, Buford, GA 30519-8151 Ph: (770) 271-4413 |
News Archive
Blue Sea Capital LLC ("Blue Sea"), a private equity firm based in Palm Beach, Florida, and with an office in El Segundo, California, announced that it has successfully closed its debut fund with $327 million of capital commitments, of which approximately 10% comes from the General Partner and its affiliates.
Researchers at the Emory Rollins School of Public Health and U.S. Centers for Disease Control and Prevention have found that high proportions of patients with prediabetes are at substantial risk for cardiovascular disease and chronic kidney disease. Their findings are published in The Lancet Diabetes & Endocrinology.
Men with fertility problems are at risk of metabolic diseases as they age, according to work being presented at the European Association of Urology conference in Munich
An international team of researchers from Canada, Australia, the Netherlands, and the United States has identified dozens of genes that could contribute to the pathology of coronavirus disease 2019 (COVID-19) and serve as potential therapeutic targets.
Celgene International Sàrl today announced results of a Phase II study of pomalidomide and dexamethasone in multiple myeloma patients who have failed both lenalidomide and bortezomib. Data were presented by Dr. Martha Lacy of the Mayo Clinic during the American Society of Clinical Oncology annual meeting.
› Verified 2 days ago